<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> effectively prevents the complications of unstable <z:mp ids='MP_0006112'>angina</z:mp> but disease reactivation has been documented following its discontinuation </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate whether this could be related to antithrombin-III <z:mpath ids='MPATH_63'>depletion</z:mpath>, 50 patients with unstable <z:mp ids='MP_0006112'>angina</z:mp> had serial determinations of activated partial thromboplastin time and of the plasma levels of <z:chebi fb="5" ids="28304">heparin</z:chebi>, antithrombin-III activity and of the thrombin-antithrombin-III complex before, during and, in a subgroup of 8 patients, 4 hours after <z:chebi fb="5" ids="28304">heparin</z:chebi> discontinuation </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> was administered intravenously at therapeutic doses for a mean of 7.6 +/- 4.1 days </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma antithrombin-III activity decreased rapidly from 1.05 +/- 0.03 to 1.0 +/- 0.03 U/ml (p &lt; 0.03) following <z:chebi fb="5" ids="28304">heparin</z:chebi> initiation with no further significant subsequent decrease </plain></SENT>
<SENT sid="4" pm="."><plain>Antithrombin-III activity returned to the control values 4 hours after the discontinuation of <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, <z:chebi fb="5" ids="28304">heparin</z:chebi> treatment is associated with small, non-cumulative and rapidly reversible decrease in antithrombin-III activity </plain></SENT>
<SENT sid="6" pm="."><plain>Reactivation of unstable <z:mp ids='MP_0006112'>angina</z:mp> after discontinuation of <z:chebi fb="5" ids="28304">heparin</z:chebi> must be explained by a mechanism other than <z:hpo ids='HP_0001976'>antithrombin-III deficiency</z:hpo> </plain></SENT>
</text></document>